Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1053/j.jvca.2025.02.037 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
The VANISH2 Trial and Its Implications for Cardiac Anesthesiologists.
J Cardiothorac Vasc Anesth
February 2025
Division of Cardiac Anesthesiology, Department of Critical Care,Anesthesia, and Pain Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA.
Catheter Ablation or Antiarrhythmic Drugs for Ventricular Tachycardia.
N Engl J Med
February 2025
University of Ottawa, Ottawa.
Background: Patients with ventricular tachycardia and ischemic cardiomyopathy are at high risk for adverse outcomes. Catheter ablation is commonly used when antiarrhythmic drugs do not suppress ventricular tachycardia. Whether catheter ablation is more effective than antiarrhythmic drugs as a first-line therapy in patients with ventricular tachycardia is uncertain.
View Article and Find Full Text PDFA randomized clinical trial of catheter ablation and antiarrhythmic drug therapy for suppression of ventricular tachycardia in ischemic cardiomyopathy: The VANISH2 trial.
Am Heart J
August 2024
School of Epidemiology and Public Health, University of Ottawa, Ottawa, Canada.
Background: Recurrent ventricular tachycardia (VT) in patients with prior myocardial infarction is associated with adverse quality of life and clinical outcomes, despite the presence of implanted defibrillators (ICDs). Suppression of recurrent VT can be accomplished with antiarrhythmic drug therapy or catheter ablation. The Ventricular Tachycardia Antiarrhythmics or Ablation In Structural Heart Disease 2 (VANISH2) trial is designed to determine whether ablation is superior to antiarrhythmic drug therapy as first line therapy for patients with ischemic cardiomyopathy and VT.
View Article and Find Full Text PDFVentricular Tachycardia with ICD Shocks: When to Medicate and When to Ablate.
Curr Cardiol Rep
September 2017
QEII Health Sciences Centre, Room 2501 B/F Halifax Infirmary 1796 Summer Street, Halifax, NS, B3H 3A7, Canada.
Purpose Of Review: Ventricular tachycardia occurrence in implantable cardioverter defibrillator (ICD) patients may result in shock delivery and is associated with increased morbidity and mortality. In addition, shocks may have deleterious mechanical and psychological effects. Prevention of ventricular tachycardia (VT) recurrence with the use of antiarrhythmic drugs or catheter ablation may be warranted.
View Article and Find Full Text PDFDurability of treatment effect with polidocanol endovenous microfoam on varicose vein symptoms and appearance (VANISH-2).
J Vasc Surg Venous Lymphat Disord
July 2015
BTG International, Philadelphia, Pa; BTG International, London, United Kingdom. Electronic address:
Objective: The objectives of this study were to assess the durability of response to treatment with polidocanol endovenous microfoam (Varithena; Provensis Ltd, a BTG International group company) and to assess the long-term safety of the study patients.
Methods: This report presents efficacy and safety data from the day after visit 5/week 8 (the primary end point of the study) through the 1-year study visit. As the approved dose concentration is 1%, this analysis focuses on those patients who were randomized to polidocanol endovenous microfoam 1% at study visit 2.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!